For or against adjuvant trastuzumab for pT1a-bN0M0 Breast Cancer patients with HER2-positive tumors: A meta-analysis of published literatures

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Zhou, Qiong ^a,b   Yin, Wenjin ^a,b   Du, Yueyao ^a,b   Lu, Jinsong ^a,b,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; PUBLICATION; RISK FACTOR; SYMPOSIUM; TRIPLE NEGATIVE BREAST CANCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PUBLICATION BIAS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84895426743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083646     Document Type: Article

References (29)

1. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 31:3997-4013.
2. Livi L, Meattini I, Saieva C, Franzese C, Di Cataldo V, et al. (2012) Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer 118:3236-3243.
3. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, et al. (2009) Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699.
4. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, et al. (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706.
5. Sanpaolo P, Barbieri V, Pedicini P, Fusco V (2012) Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis. Med Oncol 29:459-465.
6. Petrelli F, Barni S (2012) Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M breast cancer: a systematic review of the literature with a pooled-analysis. Med Oncol 29:2586-2593.
7. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, et al. (2011) Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 127:713-720.
8. Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, et al. (2010) Prognosis and outcome of small (, = 1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 15:1043-1049.
9. Park YH, Kim ST, Cho EY, Choi YL, Ok ON, et al. (2010) A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (, or=1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 119:653-661.
10. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, et al. (2011) Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11:325-331.
11. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, et al. (2010) Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer. Int J Radiat Oncol Biol Phys 77:1296-1302.
12. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684. (Pubitemid 41464706)
13. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, et al. (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27:5685-5692.
14. Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, et al. (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134.
15. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, et al. (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244.
16. Yin W, Jiang Y, Shen Z, Shao Z, Lu J (2011) Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One 6:e21030.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2.2012. Available: http://www.nccn.org/ professionals/physician-gls/pdf/breast.pdf. Accessed 2012 September 10.
18. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, et al. (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206-2223.
19. Aebi S, Davidson T, Gruber G, Cardoso F (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22: vi12-24.
20. McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, et al. (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461-5468.
21. Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, et al. (2010) Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol 28:e541-542.
22. Horio A, Fujita T, Hayashi H, Hattori M, Kondou N, et al. (2012) High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol 17:131-136.
23. Frenel JS, Rodrigues MJ, Peron J, Yann-Alexandre V, Wassermann J, et al. Impact of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2 overexpressing breast carcinomas; 2012. J Clin Oncol 30 (suppl; abstr 601).
24. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, et al. (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560. (Pubitemid 37088507)
26. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502. (Pubitemid 43854964)
27. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, et al. (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792-2798.
28. Niwinska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942-948.
29. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, et al. (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 115:325-333.